Goldfinch Bio, Inc.
Industry
- Pharmaceuticals
- Biotechnology
- Gene Therapy, Cell Therapy
- Pharmacogenetics-Pharmacogenomics
- Drug Discovery Technologies
- Genomics-Proteomics
Latest on Goldfinch Bio, Inc.
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Dragonfly Takes Back IL-12 Immunotherap
BioGeneration Ventures (BGV) and Autobahn Labs recently emerged with new sources of funding for the translation of early research into drug development platforms and therapeutic candidates. Naarden, T
Biopharmaceutical start-up financings declined 17% from $3.44bn in the first quarter to $2.84bn in the second quarter, according to Strategic Transactions . However, young drug developers continue to
Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Gilead Pays Goldfinch $55m U